Reading the tape
NASDAQ: LXRX
Lexicon Pharmaceuticals, Inc.
Healthcare · Biotechnology
Market Cap
$682.13M
52w High
$1.95
52w Low
$0.51
P/E
-11.62
Volume
1.16M
Outstanding Shares
423.68M
Price vs Fundamentals
Why The Stock Is Moving
Fundamentals are supporting the moveModerate confidence
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
1Y Price: 120.31%Revenue (TTM): 60.24%FCF (TTM): 62.27%P/S: 58th pct
What changed
The stock rose 120.31% over the last year. Revenue grew 60.24% over the trailing twelve months. Operating margin moved from -634.2% to -98.21%. Free cash flow grew 62.27% over the trailing twelve months.
What the market seems to be pricing
The stock move broadly lines up with stronger business momentum, and the shares are still only around the 58th percentile of their historical P/S range.
What would invalidate this read
Operating margin is at -98.21%. Revenue grew 60.24% — this thesis depends on that trajectory holding. If revenue growth, margins, or free cash flow roll over while the stock keeps climbing, more of the move would be coming from multiple expansion than business progress.
Company profile
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products.
CEOMichael S. Exton
SectorHealthcare
IndustryBiotechnology
Employees103
IPO dateApr 7, 2000
Valuation
Forward P/E—
EV/EBITDA-9.22
Enterprise value$445.42M
Stock splits
May 21, 2015↓ Reverse
Every 7 shares became 1
Profitability & growth
Revenue growth-79.31%
Gross margin98.86%▲1.46%vs FY2024
Operating margin-98.21%▲84.51%vs FY2024
ROE-46.81%▲65.91%vs FY2024
Analyst consensus
RatingHold
Target price$6.00▲272.67%
5
Buy
7
Hold
2
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
May 1, 2026
Q2 FY26 · EPS est -$0.05 · Revenue est $5.84M
View